130 results about "Phase fraction" patented technology

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

An apparatus and corresponding method for determining component flow rates of a multiphase fluid in a conduit, the fluid consisting of at least three known components, the method including the steps of: measuring at each of two different positions along the conduit at least four mixture quantities, typically the sound speed, the flow velocity of the multiphase fluid, the pressure and the temperature; providing a speed of sound in each of the components at the measured pressures and temperatures; providing a trial value for each of either the component flow rates or the phase fractions; using a predetermined model to calculate values for the measured mixture quantities based on the trial values for each of either the component flow rates or the phase fractions; using a predetermined error function to determine an error value; and using a predetermined optimizing algorithm to determine whether the calculated values are acceptable, and, if they are not, to provide a new trial value for each of either the component flow rates or the phase fractions. In some applications, the error function is the sum of the squares of the difference between the measured and calculated values at each point.

A flow measuring system combines a density measuring device and a device for measuring the speed of sound (SOS) propagating through the fluid flow and/or for determining the gas volume fraction (GVF) of the flow. The GVF meter measures acoustic pressures propagating through the fluids to measure the speed of sound α_mix propagating through the fluid to calculate at least gas volume fraction of the fluid and/or SOS. In response to the measured density and gas volume fraction, a processing unit determines the density of non-gaseous component of an aerated fluid flow. For three phase fluid flows, the processing unit can determine the phase fraction of the non-gaseous components of the fluid flow. The gas volume fraction (GVF) meter may include a sensing device having a plurality of strain-based or pressure sensors spaced axially along the pipe for measuring the acoustic pressures propagating through the flow.

An apparatus is provided that determines a characteristic of a multiphase fluid, such as an aerated oil and water fluid, flowing within a pipe. The apparatus includes a fluid flow meter, a water cut meter, and a density meter, wherein the density meter determines the density of the fluid flow to determine the gas volume (or void) fraction of the multiphase fluid flow. The output signal of each of the meters is provided to a multiphase flow model to provide a plurality of multiphase parameters, such as phase fraction, volumetric flow, mass flow of each of the phases of the multiphase mixture, optimized for various flow conditions. Each of the meters may be secured to the outer surface of the pipe using various means, such a clamping means.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

The translucent or opaque colored glass-ceramic article provides a cooking surface and has an adjustable light transmission in a visible range under 15%, as measured for a 4 mm sample thickness; a flaw-free upper surface with an impact resistance of greater than 18 cm breaking height, as tested with a 200 g steel ball in a falling ball test; a temperature difference resistance of greater than 500° C.; a high crystallinity with keatite mixed crystals as principal crystal phase in an interior of the glass-ceramic article and with a residual glass phase fraction of less than 8% by weight; a glassy upper surface layer of from 0.5 to 2.5 μm thick, which is substantially free of high quartz mixed crystals and which inhibits chemical reactions, and a content of enriched ingredients in the residual glass phase in the interior of the glass-ceramic and in the glassy surface layer of ΣNa₂O+K₂O+CaO+SrO+BaO+F+refining agents of from 0.2 to 1.6% by weight.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

Mixed-phase TiO₂ nanofibers prepared via a sol-gel technique followed by electrospinning and calcination are provided as photocatalysts. The calcination temperature is adjusted to control the rutile phase fraction in TiO₂ nanofibers relative to the anatase phase. Post-calcined TiO₂ nanofibers composed of 38 wt % rutile and 62 wt % anatase exhibited the highest initial rate constant of UV photocatalysis. This can be attributed to the combined influences of the fibers' specific surface areas and their phase compositions.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

The detection system for phase content rate and interface in multiphase tube flow comprises: a single-wire capacitor and probe device, and a connected C/V conversion circuit to convert the capacitor value of probe into dc voltage and send to following device, and a signal process device to control last circuit and process, display and store data. This invention eliminates effect of fluid electric feature to detection result, and realizes real-time and on-line detection with well precision.

The invention relates to bodies coated with a hard material, comprising a multi-layer coating system containing at least one Ti_1-xAl_xN hard material coating and to a multi-stage CVD method for producing the bodies. The aim of the invention is to achieve excellent adhesion of the Ti_1-xAl_xN hard material coating in bodies coated with a hard material comprising a multi-layer coating system containing at least one Ti_1-xAl_xN hard material coating and a high degree of wear resistance. According to the invention, the bodies coated with a hard material comprising a multi-layer coating system containing at least one Ti_1-xAl_xN hard material coating are characterized by the following features: the coating system consists of a) a bonding coating applied to the body, consisting of TiN, Ti(C,N) or TiC; b) a phase gradient coating that is applied to the bonding coating; and c) the single or multi-phase Ti_1-xAl_xN hard material coating or coatings applied to the phase gradient coating. The phase gradient coating consists of a TiN/h-AlN phase mixture on the side facing the bonding coating and has an increasing phase fraction of fcc-TiAlN with an increasing coating thickness, (the fraction being >50%), towards the Ti_1-xAl_xN hard material coating(s) and a corresponding simultaneous decrease in the phase fractions of TiN and h-AlN. The coating according to the invention can be used in particular for tools and components consisting of steel, hard metals, cermets and ceramics, such as for example drills, milling cutters and indexable cutting inserts.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

Methods and apparatus for measuring a phase fraction of a flow stream are disclosed. An infrared phase fraction meter includes a light source for emitting into a flow stream infrared radiation that includes first and second wavelength bands. The first wavelength band substantially transmits through first and second phases of the flow stream and is substantially absorbed by a third phase. In contrast, the second wavelength band is substantially absorbed by the second phase relative to the first and third phases. One or more detectors simultaneously detect attenuation of the first and second wavelength bands upon the infrared radiation passing through at least a portion of the flow stream, and a phase fraction of the second phase is determined based on the attenuation. As an example, the first, second and third phases are gas, water and oil, respectively, produced from a well.

The invention provides a device for metering oil-gas-water three-phase flow in thickened oil in a whole range. The device comprises a Venturi flow meter 3, a double-energy gamma ray phase fraction instrument 2, a tank 5 and a differential pressure transmitter 6, wherein the double-energy gamma ray phase fraction instrument 2 is arranged on a vertical round tube at the upstream and the downstream of the Venturi flow meter or on a throat portion of a Venturi tube and comprises a double-energy gamma ray generator and a gamma ray detector, and due to the arrangement mode of the double-energy gamma ray generator and the gamma ray detector, gamma rays emitted by the double-energy gamma ray generator can penetrate through a tube cross section of the throat portion of the Venturi tube 3 in the radial direction and arrive at the gamma ray detector; the tank 5 is located at the downstream of the Venturi tube 3 and is used for accumulating or discharging the thickened oil, the top of the tank is provided with a gas outlet, and the bottom of the tank is provided with a liquid outlet; due to the arrangement mode of the differential pressure transmitter 6, the differential pressure transmitter 6 can measure differential pressure delta P between a lower pressure tapping and a liquid level caused by accumulation of the thickened oil in the tank 5. The invention further relates to a method for metering oil-gas-water three-phase flow in the thickened oil in the whole range.

The invention relates to a method for separating and extracting cholesterol in lanolin alcohol, which comprises the following steps: carrying out molecular distillation on lanolin alcohol, collecting the light-phase fraction which is refined lanolin alcohol, heating the refined lanolin alcohol in a mixed solvent of methanol and acetone until the refined lanolin alcohol is completely dissolved, and cooling to cooling temperature, wherein the remainder of the filtrate after reduced pressure distillation is the primary concentrate of cholesterol; heating to dissolve the primary concentrate of cholesterol in acetone, cooling to precipitate, filtering, and carrying out reduced pressure distillation on the filtrate to recover the solvent, wherein the balance is the secondary concentrate of cholesterol; heating to dissolve the secondary concentrate of cholesterol in an alcohol solvent, cooling to cooling temperature, keeping the temperature for 6-12 hours, and vacuum-filtering to obtain the white acerose cholesterol crude product; and recrystallizing the cholesterol crude product through a methanol-acetone mixed solvent to obtain the refined cholesterol product. The refined cholesterol product selectively recrystallizes through the solvent to obtain the byproduct lanosterol accounting for 63-70% and the cholesterol product of which the purity is more than 90%.

Methods and apparatus determine individual phase fractions for three phases within a fluid mixture. Appropriate flow algorithms can utilize this phase fraction information with a sensed total combined flow rate of the mixture to find individual flow rates for the three phases, such as oil, water and gas. For some embodiments, a multiphase flowmeter includes an array of spatially distributed pressure sensors configured to determine a speed of sound in the mixture and any type of water cut meter, oil cut meter or gas cut meter.